|
Advanced Viral Detection Technology IG (AVDTIG)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NIAID
|
This working group seeks to develop guidelines for best practices for Next Generation Sequencing to identify viral contaminants in biological products.
|
|
Advancing American Kidney Health Initiative
|
Research Initiative
|
CDC, CMS, FDA, ASPE, ASPR, HRSA, IHS, OCR
|
NIDDK, NIEHS
|
This initiative aims to improve the lives of Americans suffering from kidney disease, expand options for American patients, and reduce healthcare costs. The initiative provides specific solutions to deliver on three goals: fewer patients developing kidney failure, fewer Americans receiving dialysis in dialysis centers, and more kidneys available for transplant. NIDDK promotes an integrated health system model of team-based clinical care based on the pragmatic experience of the IHS; Kidney Disease Program. NIDDK has developed new clinical tools and educational programs that improve the care of people with kidney disease in primary care settings. NIDDK works in collaboration with government, nonprofit, and health care organizations to raise awareness about screening for individuals at risk for kidney disease; educate individuals about how to manage their disease; provide information, training, and tools that help health care providers; and support important health systems changes.
|
|
Advancing Protection and Care for Children in Adversity: A U.S. Government Strategy for International Assistance (APCCA)
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
FIC, NICHD, NIMH
|
Interagency working group focused on Advancing Protection and Care for Children in Adversity, with a focus on developing a coordinated US government strategy for international assistance. The National Institutes of Health (NIH) funds research and evidence-based interventions, which often inform the development and refinement of other USG programs aimed at benefiting at-risk children around the globe. Several institutes and centers within the NIH fund research to build knowledge in areas related to APCCA priorities and objectives.
|
|
Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
CC, NHLBI
|
The Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) is a 31-member federal advisory committee that provides advice to the Secretary of Health and Human Services through the Assistant Secretary for Health on a range of policy issues related to blood, blood products, and tissues.
|
|
Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC)
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, FDA, HRSA
|
NICHD, NHGRI, NHLBI, NIDDK, NLM
|
The Advisory Committee on Heritable Disorders in Newborns and Children was established under the Public Health Service Act, Title XI, § 1109 (42 USC 300b-10), as amended by the Newborn Screening Saves Lives Reauthorization Act of 2014 (PL 113-240). The mission of the Advisory Committee on Heritable Disorders in Newborns and Children is to reduce morbidity and mortality in newborns and children who have or are at risk for heritable disorders. The Committee recommends that every newborn screening program include a Uniform Screening Panel that screens for 36 core disorders and 26 secondary disorders. The Committee advises the Secretary, US Department of Health and Human Services on the most appropriate application of universal newborn screening tests, technologies, policies, guidelines, and standards. Specifically, the committee provides to the Secretary, the following: Advice and recommendations concerning grants and projects authorized, awarded, or funded related to screening heritable disorders in newborns and children; technical information to develop Heritable Disorders Program policies and priorities that will enhance the ability of the state and local health agencies to provide screening; counseling and health care services for newborns and children who have or are at risk for heritable disorders, and recommendations; and advice and information to enhance, expand, or improve the ability of the Secretary to reduce mortality and morbidity from heritable disorders in newborns and children. The committee was chartered on May 7, 2015.
|
|
Advisory Committee on Immunization Practices (ACIP WG)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NIAID
|
Group is focused on influenza immunization issues such as vaccine response and effectiveness
|
|
Advisory Committee on Maternal/Pediatric RSV Vaccines (ACIP WG)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OASH, HRSA, IHS, CMS
|
NIAID
|
Group is focused on recommendation of RSV maternal immunization from Pfizer
|
|
Advisory Committee on Organ Transplantation (ACOT)
|
Committee, Work group, Advisory group, or Task Force
|
HRSA, OS
|
NIAID
|
The Advisory Committee on Organ Transplantation (ACOT) was established to assist the Department of Health and Human Services (HHS) Secretary in enhancing organ donation, ensuring that the system of organ transplantation is grounded in the best available medical science, and assuring the public that the system is as effective and equitable as possible, thereby increasing public confidence in the integrity and effectiveness of the transplantation system.
|
|
Advisory Committee on RSV Vaccines in Older Adults (ACIP WG)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OASH, CMS
|
NIAID
|
Group is focused on recommendation for RSV vaccines in older adults
|
|
Advisory Council on Blood Stem Cell Transplantation (ACBSCT) of the U.S. Department of Health and Human Services (HHS)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, CMS, FDA, HRSA
|
NHLBI
|
The Advisory Council advises the Secretary, Department of Health and Human Services and Administrator, Health Resources and Services Administration (HRSA) on matters related to the activities of the C.W. Bill Young Cell Transplantation Program and the National Cord Blood Inventory Program. The principal purpose of these programs is to make blood stem cells from adult donors and cord blood units available for patients who need a transplant to treat life-threatening conditions such as leukemia, and who lack a suitably matched relative who can be the donor.
|